www.ganbing.org    
 
设为首页
联系站长
加入收藏
 
 
   
   
 
 
购药指南
  咨询电话
 
       
  最新推荐
  • 亚太肝病学会《慢性乙…

  • 志存高远 夺银摘金——…

  • APASL2008:抗击肝脏疾…

  • 慢性乙肝抗病毒耐药管…

  • 腺苷蛋氨酸治疗肝内胆…

  • 核苷类药物治疗慢性乙…

  • 欧洲慢性乙型肝炎治疗…

  • 中药制剂深受青睐 抗丙…

  • 2007年肝病热门药品年…

  • 胸腺五肽、胸腺肽α1与…

  •   最新专题
      恩替卡韦
      阿德福韦酯
      拉米夫定|贺普丁
      乙肝病毒耐药问与答
      派罗欣
      药物性肝炎
      自身免疫性肝炎
      纤维淤胆性肝炎
      原发性胆汁性肝硬化
      乙肝疫苗
     
       
          您现在的位置: 肝病药物网 >> 丙肝 >> 丙肝药物治疗综述
       
    丙肝病毒性肝硬化发展为肝细胞癌的高危因素
    来源:Hepatology     作者:新特药房      发布时间:2008-2-21 9:02:00
     
      丙型肝炎病毒(HCV)感染所致肝硬化可发展为肝细胞癌。意大利Bruno等学者的一项前瞻性研究显示,感染基因1型HCV是肝硬化患者发生肝细胞癌的高危因素。

      研究自1989年1月至1990年12月共纳入163例HCV感染所致的肝硬化患者,其中104例患者感染基因1b型HCV,52例感染2a/c型HCV。患者每6个月接受1次超声检查,以监测肝细胞癌的发生,应用Cox回归分析评价发生肝细胞癌的独立危险因素。

      结果显示,经过平均10.7年的随访后,44例基因1b型HCV感染者发生肝细胞癌,10例基因2a/c型HCV感染者发生肝细胞癌(P=0.0001)。多因素分析显示,1b型HCV感染是发生肝细胞癌的独立危险因素。发生肝细胞癌的其他可预测因素有食管静脉曲张、男性、年龄超过60岁等。

      研究者认为,1b型HCV感染易引起肝细胞癌,此型肝硬化患者应接受严密监测以发现早期癌变。

    Hepatology. 2007 Nov;46(5):1350-6.

    Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study.

    Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU.

    Liver Unit, Department of Medicine, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan, Italy.

    Hepatocellular carcinoma (HCC) is the most frequent cause of death in patients with hepatitis C virus (HCV)-induced cirrhosis. Despite a number of studies in different populations worldwide suggesting an association between HCV genotype 1 and the risk of HCC, no consensus has emerged yet on this matter, which is still controversial. In an attempt to clarify this issue, a prospective study of 163 consecutive HCV-positive patients with cirrhosis, who were enrolled between January 1989 and December 1990, was carried out. HCC occurrence was detected by ultrasound surveillance every 6 months. Independent predictors of HCC were assessed with a Cox regression analysis. After a median follow-up of 10.7 years, 44 [4.26/100/year, confidence interval (CI) = 3.11-5.68/100/year] of 104 patients infected with genotype 1b developed HCC versus 10 (1.69/100/year, CI = 0.82-3.09/100/year) of 52 patients infected with genotype 2a/c (P = 0.0001). Multivariate analysis showed that HCV genotype 1b was independently associated with HCC development [hazard ratio (HR) = 3.02, 95% CI = 1.40-6.53]. Other predictors of HCC were esophageal varices (HR = 2.15, 95% CI = 1.03-4.47), male gender (HR = 2.12, 95% CI = 1.10-4.11), and age over 60 years (HR = 5.96, 95% CI = 1.23-28.8). Conclusion: HCV genotype 1b is associated with a statistically significant higher risk of developing HCC. Patients with cirrhosis that are infected with this genotype require more intensive surveillance for the early detection and aggressive management of neoplasia.
    我要挑错
    Google
     
       
       
    | 药房介绍 | 设为首页 | 加入收藏 | 联系我们 | 友情链接 | 网站地图 |